CN1806821A - Rhinitis-treating medicine - Google Patents
Rhinitis-treating medicine Download PDFInfo
- Publication number
- CN1806821A CN1806821A CN 200510020212 CN200510020212A CN1806821A CN 1806821 A CN1806821 A CN 1806821A CN 200510020212 CN200510020212 CN 200510020212 CN 200510020212 A CN200510020212 A CN 200510020212A CN 1806821 A CN1806821 A CN 1806821A
- Authority
- CN
- China
- Prior art keywords
- parts
- extractum
- medicine
- flos magnoliae
- polyethylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medicament for treating rhinitis, which comprises Xanthium sibiricum seeds extract 6-9 parts, gypsum concrete powder 0.2-0.7 part, dahurian angelica root extract 9-12 parts, borneo camphor 6-9 parts, magnolia flower volatile oil 0.5-1.5 parts, menthol 3-5 parts, magnolia flower extract 10-14 parts, scutellaria root extract powder 5-8 parts, polyethylene glycol 60-270 parts with an average molecular weight of above 400.
Description
Technical field
The present invention relates to the pharmaceutical technology field, relate in particular to a kind of medicine for the treatment of rhinitis.
Background technology
Rhinitis is meant that inflammation appears in nasal membrane; show as hyperemia or edema; the patient nasal obstruction occurs through regular meeting, stream clear water tears, rhinocnesmus; throat's discomfort; symptoms such as cough, Epidemiological study show that its prevalence is greatly about about 15%; have a strong impact on people's life, working and learning, the headache that is brought, nasal obstruction, sneeze are having a strong impact on patient's quality of life.Rhinitis generally comprises acute or chronic rhinitis, sinusitis, allergic rhinitis.
The western medicine of primary disease mainly is the symptomatic treatment at nasal obstruction, as select 1% ephedrine nasal drop for use, also do not have obviously and alleviate but part rhinitis patient is dripped behind the ephedrine nasal obstruction, and can cause olfactory disorder, headache, hypomnesis, and might cause " medicamentous rhinitis "; Also can select for use antihistaminic class such as chlorphenamine oral, but the side effect that has cental system to suppress; The steroid hormone oral formulations also is usually used in the treatment of allergic rhinitis, can produce water, salt, sugar, protein metabolism disorder but use always; Nasal obstruction can adopt methods such as freezing, laser, sealing, sclerosing agent than severe patient.
Can avoid the side effect of Western medicine with the treatment by Chinese herbs rhinitis, and reach the effect for the treatment of both the principal and secondary aspects of a disease.The Chinese patent medicine of treatment rhinitis mainly contains QIANBAI BIYAN PIAN, XINQIN granule etc. at present, but still can not satisfy patient's medication needs, because of directly being used as medicine of having with the crude drug powder without extracting, problem such as be difficult to solve the existence of medical material self antibacterial, microorganism and grow, thereby make the effect duration of medicine short, not easy to store; Adjuvant that has such as starch or cane sugar content height, active constituent content is lower, so dose big, take inconvenience.
Summary of the invention
Purpose of the present invention just provides a kind of medicine for the treatment of rhinitis, and this medicine is used for the treatment of chronic rhinitis and allergic rhinitis determined curative effect, drug safety, little, the taking convenience of dose, and with low cost.
The technical solution adopted for the present invention to solve the technical problems is: a kind of medicine for the treatment of rhinitis, and it contains 6-9 part Fructus Xanthii extractum, 0.2-0.7 part Gypsum Fibrosum extract powder, 9-12 part Radix Angelicae Dahuricae extractum, 6-9 part Borneolum Syntheticum, 0.5-1.5 part Flos Magnoliae volatile oil, 3-5 part Mentholum, 10-14 part Flos Magnoliae extractum, 5-8 part Radix Scutellariae extractum powder, 60-270 part Polyethylene Glycol; And the mean molecule quantity of Polyethylene Glycol is more than 400.
In the medicine of above-mentioned treatment rhinitis, the weight proportion of each component is preferably: 7-8 part Fructus Xanthii extractum, 0.3-0.6 part Gypsum Fibrosum extract powder, 10-11 part Radix Angelicae Dahuricae extractum, 7-8 part Borneolum Syntheticum, 0.8-1.2 part Flos Magnoliae volatile oil, 3.5-4.5 part Mentholum, 11-13 part Flos Magnoliae extractum, 5.5-7.5 part Radix Scutellariae extractum powder, 65-240 part Polyethylene Glycol.More preferably: 7.5 parts of Fructus Xanthii extractum, 0.44 part of Gypsum Fibrosum extract powder, 10.35 parts of Radix Angelicae Dahuricae extractum, 7.5 parts of Borneolum Syntheticums, 1 part of Flos Magnoliae volatile oil, 3.75 parts of Mentholums, 12.03 parts of Flos Magnoliae extractum, 6.325 parts of Radix Scutellariae extract powders, 70-180 part Polyethylene Glycol.Wherein, preferred any one or a few in Polyethylene Glycol 400, Macrogol 600, Macrogol 4000, polyethylene glycol 6000 etc. of Polyethylene Glycol.
Needs according to different preparations, can also contain the other medicines composition in the medicine of above-mentioned treatment rhinitis or/and pharmaceutic adjuvant, and the other medicines composition is for being used for the treatment of Chinese medicine extract or active constituents of medicine such as Flos Magnoliae extract, the baicalin etc. of rhinitis with above-mentioned each compatibility of drugs; Pharmaceutic adjuvant is any one or a few in starch, dextrin, glycerol, vegetable oil, tween, gelatin and Cera Flava etc. preferably.
Dosage form preferred tablet, hard capsule, soft capsule, drop pill or the granule of the medicine of above-mentioned treatment rhinitis.Further preferred drop pill, and the component of this drop pill is preferably: 7-8 part Fructus Xanthii extractum, 0.3-0.6 part Gypsum Fibrosum extract powder, 10-11 part Radix Angelicae Dahuricae extractum, 7-8 part Borneolum Syntheticum, 0.8-1.2 part Flos Magnoliae volatile oil, 3.5-4.5 part Mentholum, 11-13 part Flos Magnoliae extractum, 5.5-7.5 part Radix Scutellariae extractum powder, 65-240 part Polyethylene Glycol; More preferably: 7.5 parts of Fructus Xanthii extractum, 0.44 part of Gypsum Fibrosum extract powder, 10.35 parts of Radix Angelicae Dahuricae extractum, 7.5 parts of Borneolum Syntheticums, 1 part of Flos Magnoliae volatile oil, 3.75 parts of Mentholums, 12.03 parts of Flos Magnoliae extractum, 6.325 parts of Radix Scutellariae extractum powder, 70-180 part Macrogol 4000 or polyethylene glycol 6000s.
The Fructus Xanthii extractum of mentioning in the medicine of the present invention, Radix Scutellariae extractum powder, Flos Magnoliae extractum, Flos Magnoliae volatile oil, Radix Angelicae Dahuricae extractum and Gypsum Fibrosum extract powder can be bought from market, and also can distinguishing by the following method, oneself prepares:
(1) preparation of Fructus Xanthii extractum: get Fructus Xanthii and be ground into coarse powder, add 60-95% ethanol, reflux 2-3 time, filter, merging filtrate reclaims ethanol, add suitable quantity of water, stir, get oil reservoir after leaving standstill, discard water liquid, every 1000g oil adds 5000g starch, mixing, cold drying, be ground into fine powder, promptly.
(2) preparation of Radix Scutellariae extractum powder: get Radix Scutellariae and decoct with water 2-3 time, filter, merging filtrate is concentrated in right amount, with hydrochloric acid adjust pH to 1～2, in 80 ℃ of insulations 1 hour, leaves standstill, and filters, and precipitate washes with water to neutrality, 60 ℃ of oven dry, is ground into fine powder, promptly.
(3) preparation of Flos Magnoliae extractum and Flos Magnoliae volatile oil: Flos Magnoliae put extracts volatile oil in the volatile oil extractor, with volatile oil in addition device preserve, promptly get Flos Magnoliae volatile oil.Residue decocts with water 2-3 time, filters, and filtrate is concentrated into dried, promptly gets Flos Magnoliae extractum.
(4) preparation of Radix Angelicae Dahuricae extractum: Radix Angelicae Dahuricae is decocted with water 2-3 time, leave standstill, filter, merging filtrate is concentrated in right amount, puts coldly, add ethanol and make and contain the alcohol amount and reach 45%, mixing, standing over night filters, and gets filtrate recycling ethanol, be concentrated into dried, promptly.
(5) preparation of Gypsum Fibrosum extract powder: Gypsum Fibrosum is decocted with water 2-3 time, leave standstill, filter, merging filtrate concentrates, dry by the fire in, be ground into fine powder, promptly.
More than each component also can be by the preparation of other conventional method.
The preparation of medicine of the present invention: can be prepared from by the common process of different dosage form medicine, get final product.
Compared with prior art, the invention has the beneficial effects as follows: the raw materials used medicine wide material sources of (1) this medicine are easy to get, and are cheap, and preparation method is simple, so cost is lower.(2) contain Polyethylene Glycol in the medicine of the present invention, can obviously improve bioavailability of medicament, thereby the curative effect of medicine of the present invention is significantly improved.(3) choice of drug extract of the present invention is a raw material, have and feed intake accurately, the active constituent content height, quality controllable, dose is little, the characteristics of taking convenience, and problem such as do not have material medicine directly to pulverize to be used as medicine the existence of the antibacterial that causes, microorganism and grow, thus the effect duration of medicine grow, easy to store.(4) compare with chemical medicine, poisonous side effect of medicine of the present invention is less, and safety is good.
For confirming medicine excellent curative of the present invention and safety, the inventor has carried out pharmacodynamics and acute toxicity test is investigated.The research method and the result of the test that are adopted are as follows:
(1) test material
Medicine and reagent: low dose group of the present invention (dosage: 0.25g/kg), (dosage: 0.5g/kg), this high dose group (dosage: 1g/kg) of dosage group among the present invention.The drugs compared (0.25g/kg) that does not contain Polyethylene Glycol.Dexamethasone acetate tablets, Tianjin pharmaceutcal corporation, Ltd produces.Dimethylbenzene, chemical reagent factory in Chengdu produces.Radix Tripterygii Wilfordii tablet, Huangshi pharmaceutical factory produces.
Drug weight proportioning of the present invention is as follows: 7.5 parts of Fructus Xanthii extractum, 0.44 part of Gypsum Fibrosum extract powder, 10.35 parts of Radix Angelicae Dahuricae extractum, 7.5 parts of Borneolum Syntheticums, 1 part of Flos Magnoliae volatile oil, 3.75 parts of Mentholums, 12.03 parts of Flos Magnoliae extractum, 6.325 parts of Radix Scutellariae extractum powder, 75 parts of Macrogol 4000s.
The drugs compared weight proportion that does not contain Polyethylene Glycol is as follows: 7.5 parts of Fructus Xanthii extractum, 0.44 part of Gypsum Fibrosum extract powder, 10.35 parts of Radix Angelicae Dahuricae extractum, 7.5 parts of Borneolum Syntheticums, 1 part of Flos Magnoliae volatile oil, 3.75 parts of Mentholums, 12.03 parts of Flos Magnoliae extractum, 6.325 parts of Radix Scutellariae extractum powder.
Animal: Kunming mouse, the SD rat is provided by institute of antibiotics, Sichuan Experimental Animal Center.
(2) test method and result
1. the influence of xylol induced mice ear swelling
Choose 60 Kunming mouses, male, body weight 18～22g is divided into 6 groups at random by body weight, 10 every group.Press the listed dosage of table 1, gastric infusion, matched group is irritated stomach isometric(al) distilled water, for three days on end, and every day 1 time, 60min after the last administration, each treated animal is applied to auricle two sides, a mice left side with dimethylbenzene 50 μ l and causes inflammation, cuts ears after causing scorching 30min, and hammer is got ears same area auricle, weigh, be calculated as follows swelling degree and inhibitory rate of intumesce.The results are shown in Table 1.
Swelling degree=cause inflammation is picked up the ears, and to cause the inflammation sheet of picking up the ears heavy for sheet weight-non-
The influence of table 1 xylol induced mice ear swelling (x ± SD)
| Group | Dosage * number of times (g/kg * c) | Mus number (only) | Swelling degree (mg) | Inhibitory rate of intumesce (%) |
| Dosage medicine group of the present invention low dosage does not contain the drugs compared dexamethasone tablet group of polyethylene glycol in the control group medicine group of the present invention high dose medicine group of the present invention | Equal-volume distilled water * 31 * 3 0.5 * 3 025 * 3 0.25 * 3 0.03 * 3 | 10 10 10 10 10 10 | 10.7±1.9 6.5±1.7 ** 7.2±2.1 ** 7.6±2.4 * 8.5±2.0 6.6±2.1 ** | - 39.25 32.71 28.97 20.56 38.32 |
Annotate: each administration group and matched group are relatively
*P＜0.05;
*P＜0.01;
* *P＜0.001.
Table 1 shows that medicine xylol induced mice ear swelling of the present invention has remarkable inhibitory action (* * P＜0.01), illustrates that medicine of the present invention has significant antiinflammatory action.
2. to the influence of capillary of skin permeability
72 of rats, male and female half and half, divide 6 groups at random, every group 12,, press the listed dosage of table 2 in the both sides depilation of preceding 24 hours spines of test, behind gastric infusion or normal saline (matched group) 2h, inject the normal saline solution 0.1ml of histamine (including the 80 μ g of histamine) at every back part of animal both sides depilation place Intradermal, the 0.5% azovan blue solution 0.5ml of intravenous injection simultaneously, the size of the subcutaneous locus coeruleus area of mensuration after 30 minutes.The results are shown in Table 2.
The influence of table 2 pair capillary of skin permeability (x ± SD)
| Group | Dosage (g/kg) | Mus number (only) | Locus coeruleus area (cm 2) |
| The time do not contain the drugs compared dexamethasone tablet group of polyethylene glycol according to dosage medicine group of the present invention low dosage in the group medicine group high dose of the present invention medicine group of the present invention | Equal-volume distilled water 1 0.5 0.25 0.25 0.03 | 12 12 12 12 12 12 | 2.59±1.11 1.41±0.75 *** 1.78±1.15 ** 1.89±1.24 ** 1.95±1.42 ** 0.73±0.14 *** |
Annotate: each administration group and model group are relatively
*P＜0.05;
*P＜0.01;
* *P＜0.001.
Table 2 shows, medicine of the present invention can obviously suppress the increase of the capillary of skin permeability that histamine causes, can alleviate the swelling that is produced by inflammation, alleviates nasal obstruction.
3. to the influence of mice passive cutaneous anaphylaxis, PCA
Get 10 of male mices, about 20 grams of body weight, two hind paws of every mice of Radix Trichosanthis gel aluminum hydroxide suspension (face time spent be dissolved among the 5% gel aluminum hydroxide 1ml with the 2.5mg Radix Trichosanthis) are injected 0.05ml, two soles are total to 0.1ml, after 15 days, broken end is got blood, and the centrifuging and taking antiserum is standby.Other gets 60 of male mices, and body weight 20 ± 1g is divided into 6 groups at random, 10 every group, presses the listed dosage of table 3, continuous 4 days of of every day gastric infusion or distilled water (matched group).Get above-mentioned antiserum and add normal saline and be diluted to 1: 5, each Mus stomach wall intradermal injection 2 point (at a distance of 0.2cm), every some 0.03ml.And successive administration 2 days, after 12 hours, 0.2ml/ is only for the Radix Trichosanthis of every mouse mainline Radix Trichosanthis 2.5mg/ml (with the preparation of 1% azovan blue, one physiology saline) in the last administration, sacrificed by decapitation animal after 20 minutes, the upset skin of abdomen, the diameter of mensuration locus coeruleus the results are shown in Table 3.
The influence of table 3 pair mice passive anaphylaxis (x ± SD)
| Group | Dosage (g/kg) | Mus number (only) | Locus coeruleus diameter (cm) |
| Dosage medicine group of the present invention low dosage does not contain the drugs compared leigongteng tablets group of polyethylene glycol in the control group medicine group of the present invention high dose medicine group of the present invention | Equal-volume distilled water 1 0.5 0.25 0.25 0.02 | 10 10 10 10 10 10 | 1.29±0.20 0.43±0.27 *** 0.52±0.31 ** 0.70±0.28 ** 0.83±0.21 * 0.31±0.08 *** |
Annotate: each administration group and matched group are relatively
*P＜0.05;
*P＜0.01;
* *P＜0.001.
Table 3 experimental result shows that medicine of the present invention has obvious inhibitory action to the mice passive cutaneous anaphylaxis, PCA, confirms medicine tool anti-allergic effects of the present invention, can be used for allergic rhinitis.
4. acute toxicity test
The inventor has carried out the acute toxicity test investigation with mice to medicine of the present invention, and the result is: when the maximum dosage-feeding of medicine mouse stomach of the present invention administration is 51g/kg/24h, do not have a mice overt toxicity reaction symptom to occur; This dosage is about 1020 times of 60kg body weight adult's clinical oral administration day dosage (0.05g/kg).The result shows that safety of medicine dosage range of the present invention is bigger.
The specific embodiment
The present invention is described in further detail below in conjunction with the specific embodiment.
Embodiment one
Medicine of the present invention is a drop pill, and its component is: 7.5 parts of Fructus Xanthii extractum, 0.44 part of Gypsum Fibrosum extract powder, 10.35 parts of Radix Angelicae Dahuricae extractum, 7.5 parts of Borneolum Syntheticums, 1 part of Flos Magnoliae volatile oil, 3.75 parts of Mentholums, 12.03 parts of Flos Magnoliae extractum, 6.325 parts of Radix Scutellariae extractum powder, 80 parts of Macrogol 4000s.
Make the drop pill of certain specification by the common process of preparation drop pill.
Embodiment two
Medicine of the present invention is a drop pill, and its component is: 7 parts of Fructus Xanthii extractum, 0.6 part of Gypsum Fibrosum extract powder, 10 parts of Radix Angelicae Dahuricae extractum, 7 parts of Borneolum Syntheticums, 0.8 part of Flos Magnoliae volatile oil, 4.5 parts of Mentholums, 11 parts of Flos Magnoliae extractum, 5 parts of Radix Scutellariae extractum powder, 70 parts of polyethylene glycol 6000s.
Make the drop pill of certain specification by the common process of preparation drop pill.
Embodiment three
Medicine of the present invention is a drop pill, and its component is: 8 parts of Fructus Xanthii extractum, 0.3 part of Gypsum Fibrosum extract powder, 9 parts of Radix Angelicae Dahuricae extractum, 8 parts of Borneolum Syntheticums, 0.5 part of Flos Magnoliae volatile oil, 3.5 parts of Mentholums, 13 parts of Flos Magnoliae extractum, 5.5 parts of Radix Scutellariae extractum powder, 240 parts of Macrogol 4000s.
Make the drop pill of certain specification by the common process of preparation drop pill.
Embodiment four
Medicine of the present invention is a drop pill, and its component is: 6 parts of Fructus Xanthii extractum, 0.7 part of Gypsum Fibrosum extract powder, 11 parts of Radix Angelicae Dahuricae extractum, 9 parts of Borneolum Syntheticums, 1.2 parts of Flos Magnoliae volatile oil, 3 parts of Mentholums, 10 parts of Flos Magnoliae extractum, 7.5 parts of Radix Scutellariae extractum powder, 65 parts of Polyethylene Glycol 2500.
Make the drop pill of certain specification by the common process of preparation drop pill.
Embodiment five
Medicine of the present invention is a drop pill, and its component is: 9 parts of Fructus Xanthii extractum, 0.2 part of Gypsum Fibrosum extract powder, 12 parts of Radix Angelicae Dahuricae extractum, 6 parts of Borneolum Syntheticums, 1.5 parts of Flos Magnoliae volatile oil, 5 parts of Mentholums, 14 parts of Flos Magnoliae extractum, 8 parts of Radix Scutellariae extractum powder, 120 parts of Macrogol 4000s and 60 parts of Polyethylene Glycol 2500.
Make the drop pill of certain specification by the common process of preparation drop pill.
Embodiment six
Medicine of the present invention is a drop pill, and its component is: 7.5 parts of Fructus Xanthii extractum, 0.5 part of Gypsum Fibrosum extract powder, 10.5 parts of Radix Angelicae Dahuricae extractum, 7.2 parts of Borneolum Syntheticums, 0.9 part of Flos Magnoliae volatile oil, 4 parts of Mentholums, 12 parts of Flos Magnoliae extractum, 6 parts of Radix Scutellariae extractum powder, 200 parts of Macrogol 4000s and 70 parts of polyethylene glycol 6000s.
Make the drop pill of certain specification by the common process of preparation drop pill.
Embodiment seven
Medicine of the present invention is a soft capsule, and the component of its content is: 7.5 parts of Fructus Xanthii extractum, 0.44 part of Gypsum Fibrosum extract powder, 10.35 parts of Radix Angelicae Dahuricae extractum, 7.5 parts of Borneolum Syntheticums, 1 part of Flos Magnoliae volatile oil, 3.75 parts of Mentholums, 12.03 parts of Flos Magnoliae extractum, 6.325 parts of Radix Scutellariae extractum powder, 27 parts of vegetable oil and 60 parts of PEG400s; Soft capsule shell component and method routinely made.
Make the soft capsule of certain specification by the common process of preparation soft capsule.
Embodiment eight
Medicine of the present invention is a soft capsule, and the component of its content is: 8 parts of Fructus Xanthii extractum, 0.40 part of Gypsum Fibrosum extract powder, 10.25 parts of Radix Angelicae Dahuricae extractum, 7.8 parts of Borneolum Syntheticums, 1.1 parts of Flos Magnoliae volatile oil, 3.5 parts of Mentholums, 12.5 parts of Flos Magnoliae extractum, 6.5 parts of Radix Scutellariae extractum powder, 24 parts of vegetable oil, 10 parts of gelatin, 0.05 part of Tween 80 and 75 parts of Macrogol 600s; Soft capsule shell component and method routinely made.
Make the soft capsule of certain specification by the common process of preparation soft capsule.
Embodiment nine
Medicine of the present invention is a soft capsule, and the component of its content is: 7.8 parts of Fructus Xanthii extractum, 0.55 part of Gypsum Fibrosum extract powder, 11 parts of Radix Angelicae Dahuricae extractum, 8 parts of Borneolum Syntheticums, 1 part of Flos Magnoliae volatile oil, 3 parts of Mentholums, 12 parts of Flos Magnoliae extractum, 7 parts of Radix Scutellariae extract powders, 18 parts of vegetable oil, 5 parts of glycerol, 85 parts of Polyethylene Glycol 800 and 2 parts of Cera Flavas; Soft capsule shell component and method routinely made.
Make the soft capsule of certain specification by the common process of preparation soft capsule.
Embodiment ten
Medicine of the present invention is a tablet, and its component is: 7.5 parts of Fructus Xanthii extractum, 0.4 part of Gypsum Fibrosum extract powder, 10.35 parts of Radix Angelicae Dahuricae extractum, 7.5 parts of Borneolum Syntheticums, 1 part of Flos Magnoliae volatile oil, 3.5 parts of Mentholums, 12 parts of Flos Magnoliae extractum, 6.5 parts of Radix Scutellariae extractum powder, 90 parts of Polyethylene Glycol 2500 and 20 parts of dextrin.
Make the tablet of certain specification by the common process of preparation tablet.
Embodiment 11
Medicine of the present invention is a hard capsule, and its component is: 8 parts of Fructus Xanthii extractum, 0.65 part of Gypsum Fibrosum extract powder, 10 parts of Radix Angelicae Dahuricae extractum, 7.8 parts of Borneolum Syntheticums, 1.1 parts of Flos Magnoliae volatile oil, 4 parts of Mentholums, 13 parts of Flos Magnoliae extractum, 6.5 parts of Radix Scutellariae extractum powder, 100 parts of polyethylene glycol 6000s and 30 parts of starch.
Make the hard capsule of certain specification by the common process of preparation hard capsule.
Embodiment 12
Medicine of the present invention is a granule, and its component is: 7 parts of Fructus Xanthii extractum, 0.6 part of Gypsum Fibrosum extract powder, 10 parts of Radix Angelicae Dahuricae extractum, 6 parts of Borneolum Syntheticums, 0.5 part of Flos Magnoliae volatile oil, 5 parts of Mentholums, 14 parts of Flos Magnoliae extractum, 5 parts of Radix Scutellariae extractum powder, 260 parts of Macrogol 4000s, 40 portions of sucrose.
Make the granule of certain specification by the common process of preparation granule.
Claims (8)
1, a kind of medicine for the treatment of rhinitis, it contains 6-9 part Fructus Xanthii extractum, 0.2-0.7 part Gypsum Fibrosum extract powder, 9-12 part Radix Angelicae Dahuricae extractum, 6-9 part Borneolum Syntheticum, 0.5-1.5 part Flos Magnoliae volatile oil, 3-5 part Mentholum, 10-14 part Flos Magnoliae extractum, 5-8 part Radix Scutellariae extractum powder, 60-270 part Polyethylene Glycol; And the mean molecule quantity of Polyethylene Glycol is more than 400.
2, the medicine of treatment rhinitis according to claim 1 is characterized in that, the weight proportion of described each component is: 7-8 part Fructus Xanthii extractum, 0.3-0.6 part Gypsum Fibrosum extract powder, 10-11 part Radix Angelicae Dahuricae extractum, 7-8 part Borneolum Syntheticum, 0.8-1.2 part Flos Magnoliae volatile oil, 3.5-4.5 part Mentholum, 11-13 part Flos Magnoliae extractum, 5.5-7.5 part Radix Scutellariae extractum powder, 65-240 part Polyethylene Glycol.
3, the medicine of treatment rhinitis according to claim 2 is characterized in that: the weight proportion of described each component is: 7.5 parts of Fructus Xanthii extractum, 0.44 part of Gypsum Fibrosum extract powder, 10.35 parts of Radix Angelicae Dahuricae extractum, 7.5 parts of Borneolum Syntheticums, 1 part of Flos Magnoliae volatile oil, 3.75 parts of Mentholums, 12.03 parts of Flos Magnoliae extractum, 6.325 parts of Radix Scutellariae extractum powder, 70-180 part Polyethylene Glycol.
4, the medicine of treatment rhinitis according to claim 1 is characterized in that: described Polyethylene Glycol is to be selected from PEG400, Macrogol 600, Macrogol 4000, the polyethylene glycol 6000 any one or a few.
5, the smooth medicine of treatment nose according to claim 1, it is characterized in that: also contain the other medicines composition in this medicine or/and pharmaceutic adjuvant, and pharmaceutic adjuvant is to be selected from starch, dextrin, glycerol, vegetable oil, tween, gelatin and the Cera Flava any one or a few.
6, the medicine of treatment rhinitis according to claim 1 is characterized in that: the dosage form of this medicine is tablet, hard capsule, soft capsule, drop pill or granule.
7, the medicine of treatment rhinitis according to claim 6, it is characterized in that: the dosage form of this medicine is a drop pill, and its component is: 7-8 part Fructus Xanthii extractum, 0.3-0.6 part Gypsum Fibrosum extract powder, 10-11 part Radix Angelicae Dahuricae extractum, 7-8 part Borneolum Syntheticum, 0.8-1.2 part Flos Magnoliae volatile oil, 3.5-4.5 part Mentholum, 11-13 part Flos Magnoliae extractum, 5.5-7.5 part Radix Scutellariae extractum powder, 65-240 part Polyethylene Glycol.
8, the medicine of treatment rhinitis according to claim 7 is characterized in that: the component of described drop pill is: 7.5 parts of Fructus Xanthii extractum, 0.44 part of Gypsum Fibrosum extract powder, 10.35 parts of Radix Angelicae Dahuricae extractum, 7.5 parts of Borneolum Syntheticums, 1 part of Flos Magnoliae volatile oil, 3.75 parts of Mentholums, 12.03 parts of Flos Magnoliae extractum, 6.325 parts of Radix Scutellariae extractum powder, 70-180 part Macrogol 4000 or polyethylene glycol 6000s.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510020212 CN1806821A (en) | 2005-01-20 | 2005-01-20 | Rhinitis-treating medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510020212 CN1806821A (en) | 2005-01-20 | 2005-01-20 | Rhinitis-treating medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1806821A true CN1806821A (en) | 2006-07-26 |
Family
ID=36839031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510020212 Pending CN1806821A (en) | 2005-01-20 | 2005-01-20 | Rhinitis-treating medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1806821A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101185673B (en) * | 2007-11-07 | 2011-01-12 | 李会敏 | Medicine for treating nasosinusitis |
| CN101491578B (en) * | 2008-12-31 | 2011-06-22 | 四川禾邦阳光制药股份有限公司 | A kind of cocklebur rhinitis dropping pill and preparation method thereof |
| CN101474256B (en) * | 2008-12-31 | 2011-11-30 | 四川禾邦阳光制药股份有限公司 | Siberian cocklebur fruit soft capsule preparation for treating rhinitis and preparation method thereof |
| CN101474255B (en) * | 2008-12-31 | 2011-11-30 | 四川禾邦阳光制药股份有限公司 | Detection method of siberian cocklebur fruit capsule for treating rhinitis |
| CN108686058A (en) * | 2018-07-12 | 2018-10-23 | 云南大理瑞鹤药业有限公司 | Seven apertures rhinitis-treating spray and preparation method thereof |
| CN111743835A (en) * | 2020-07-07 | 2020-10-09 | 福建维真园医药科技有限公司 | Composition of mucosa repair antibacterial liquid and application |
| WO2023014176A1 (en) * | 2021-08-05 | 2023-02-09 | 이정호 | Korean traditional medicine composition, for external use, for treating nasal diseases |
-
2005
- 2005-01-20 CN CN 200510020212 patent/CN1806821A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101185673B (en) * | 2007-11-07 | 2011-01-12 | 李会敏 | Medicine for treating nasosinusitis |
| CN101491578B (en) * | 2008-12-31 | 2011-06-22 | 四川禾邦阳光制药股份有限公司 | A kind of cocklebur rhinitis dropping pill and preparation method thereof |
| CN101474256B (en) * | 2008-12-31 | 2011-11-30 | 四川禾邦阳光制药股份有限公司 | Siberian cocklebur fruit soft capsule preparation for treating rhinitis and preparation method thereof |
| CN101474255B (en) * | 2008-12-31 | 2011-11-30 | 四川禾邦阳光制药股份有限公司 | Detection method of siberian cocklebur fruit capsule for treating rhinitis |
| CN108686058A (en) * | 2018-07-12 | 2018-10-23 | 云南大理瑞鹤药业有限公司 | Seven apertures rhinitis-treating spray and preparation method thereof |
| CN111743835A (en) * | 2020-07-07 | 2020-10-09 | 福建维真园医药科技有限公司 | Composition of mucosa repair antibacterial liquid and application |
| WO2023014176A1 (en) * | 2021-08-05 | 2023-02-09 | 이정호 | Korean traditional medicine composition, for external use, for treating nasal diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1210047C (en) | Medicine for treating cold and preparation method thereof | |
| CN101045106A (en) | Traditional Chinese medicine for treating lung heat cough and high fever | |
| CN1939443A (en) | Preparation and use for loquat-leaf extract | |
| CN1883618A (en) | Effective parts of cirald daphne bark, preparation method and application thereof | |
| CN1806821A (en) | Rhinitis-treating medicine | |
| CN1397560A (en) | Process for extracting general platycodoside and platycoligenin D from platycodon root, its medical application and its Chinese medicine | |
| CN1965873A (en) | Chinese medicinal extract having blood sugar-lowering activity, its preparation process, composition and use | |
| CN110755580B (en) | Traditional Chinese medicine composition with analgesic effect and application thereof | |
| CN1803155A (en) | Medicine for curing rhinitis | |
| CN1453295A (en) | Medicinal polysaccharide component of spinulate hedgehog fungus, its prepn and medicinal composition | |
| CN1724019A (en) | Medicine for relieving-cough and asthma | |
| CN1261125C (en) | Chinese herbal medicine and for treating acute rhinitis and chronic rhinitis as well as its preparing method | |
| CN1244332C (en) | Sarcandra extract and its application | |
| CN111714521B (en) | A kind of Periplaneta americana intestinal flora metabolite extract, its preparation method and its application in the preparation of anti-inflammatory or anti-ulcer products | |
| CN1548079A (en) | Active part and effective component of Four Drug Decoction | |
| CN1316980C (en) | Medicinal use of spanish moss of Chinese traditional medicine | |
| CN1259938C (en) | Chinese medicine compound preparation for treating cough and its preparing method | |
| CN1500505A (en) | Medication composition for children 's virus pneumonia and its preparation method | |
| CN1267095C (en) | Application use of dihydromyricetrin | |
| CN1256942C (en) | Application of dihydromyricetrin | |
| CN1857364A (en) | Medicine containing honeysuckle extract and its preparing method | |
| CN1843418A (en) | Chinese medicine extract for treating gastroenteritis and Chinese medicine composition containing the extract | |
| CN1596954A (en) | Red ginseng and ophiopogon root preparation and its making method | |
| CN1850219A (en) | Shenling Chinese medicine preparation for strengthening body resistance | |
| CN1429834A (en) | Fructus gleditsiae total saponin, its preparation method and use in preparation of medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20060726 |